Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
BSS (Balanced Salt Solution) is an irrigation solution approved by the FDA in 1997 for ophthalmic surgical use. It is formulated to maintain anterior chamber stability and corneal clarity during intraocular procedures. The solution works by providing a physiologically balanced medium that mimics aqueous humor composition.
Product is in late-stage lifecycle with declining Part D utilization, indicating a shrinking team and reduced promotional investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Evaluation of Balanced Salt Solution During Cataract Surgery
Spinal Cord Stimulation Versus Instrumentation for FBSS
First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts
Hospital Avoidance Strategies for ABSSSI
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Worked on BSS at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BSS offers limited career advancement potential as the product is mature, low-growth, and approaching loss of exclusivity. Roles are primarily focused on defensive commercial strategies, cost optimization, and maintaining existing market share rather than driving innovation or expansion.